Morning, everybody. It is John here. Welcome to our Q2 2026 report. I think we have had a quarter of positive progression, which we are very pleased with. You can see it's another quarter of double-digit organic revenue growth and margin expansion, which is really what we're aiming for. Strong organic growth of 11.8%. And this is our sixth quarter of improved margins. So we are very pleased with that. It's a record that we're proud of and hope to continue as we go forward.
Just a reminder for everybody, this particular quarter has a very strong comparable base. Last year we made significant movements upwards. So it's even more pleasing to see the progress that we've actually made. And a year or so ago, probably just a year and a quarter, there was a lot of talk about India and what we were going to do in terms of the growth for India. But you can see that over Q1 and Q2, we've had very positive progression and really strong growth percentages. Our diagnostic services business has performed very well. There is a level of consistency happening within that division, which we are delighted with. And it is all credit to their hard work. And we have consistency of increasing our fee-for-service revenue streams, which is where our main focus is. And leverage was at 2.9. So revenue is 640.4 million, which is very respectable in terms of the growth rate. You can see that from an organic perspective. It is 11.8%, which is very credible indeed. Adjusted EBITDA was 109.2, which is very pleasing to see and reflects our progress. And you can see also with the Adjusted EBITDA margin at 17.1%, the increase there is not as big. But as I said, there is a very high comparable. So just to see that move in the right direction is very positive for us. Operating cash flow was 73.6 million. That is up 28.44%. So really good generation.
From our perspective, that is quite important for us because as we do that, it gives us more choices. Leverage, as I said, is at 2.9, that is down from where we were at year end at 3.1. And of course, it's improved quite considerably if we look year on year from 3.6 last year to 2.9. So, we have produced a good, solid set of numbers. We are happy with that if we move forward and just look at the revenue and the progression of the revenue streams. Another good quarter.
Revenue produced at expected levels. So we are happy with that. Revenue by country is very steady. But you can see a strong quarter in India in euros up 23%, and in local currency much higher. As I said, at this time last year, it was a big area of debate for us. So it is really pleasing to see the team have continued their progress and have momentum inside that business and revenue by payer.
A little bit of change in mix is happening here with different things going on, but very good strength is coming through from fee for service, which is our biggest stream. And it's obviously the stream that we want to concentrate on a lot. And it's good to see that growth in governmental revenue streams in terms of public pay, as there are lots of micro changes happening there that are affecting it. And we know that in terms of our funded business, we want to continue to develop that, but it is pleasing to see that we have got growth starting to come through in Poland from some of the initiatives that we have put in place.
So that's very, very positive.
If you look at healthcare services, there was solid performance by healthcare services; again, this is the area where the comparable base was likely the highest. So, we need to bear that in mind, but revenue growth was 6.9%, with organic growth of 12.2%. So, very, very good. And price accounted for 55.2% of that. So, you know, quite a solid mix that we have there, as I said, with India, 23.1% revenue growth in India in euros, but 39.6% in local currencies. So 34.4% last quarter towards 40% this quarter. Good momentum in that particular business. Fee for service and other areas performed well. Sports and wellness continues to be strong for us. And we will continue to develop that proposition very strongly. Memberships remain relatively unchanged. As I say, Poland grew, while there was some membership fall in Romania. Quite a bit of that was contract management. As we manage the profitable and unprofitable accounts, most importantly related to the fee for service, our ability to create relationships with people looking for those kinds of solutions is growing quite strongly. Revenue was 442.8 million. So, 6.9 percent is a good EBITDA margin. 18.4%. So a slight change there against the comparable membership. Memberships are relatively flat and revenue by country is not changing dramatically. When you see the minuses, please bear in mind that we still have Hungary in these comparables. So that affects that particular indicator, and as we move to diagnostics, we will see that it's a strong growth and improved profitability. So, congratulations to that team. Good revenue growth increased by 8.5 percent, and organic growth was up 10.9 percent. And a good proportion of that is in price. And please remember that from a German perspective, the ability to move prices is almost absolutely zero. So, very credible performance by the diagnostics team. Fee-for-service. Strong. As we said, that is the area of focus. So that is really pleasing to see operational leverage coming through. And of course, with the diagnostic tests, the mix is quite important in terms of the different types of tests that you do. We have always focused on making sure we have a reputation for not only covering the basics but also covering the more advanced side of healthcare. So that's great. Ukraine continues to deliver a really solid performance for us. I mean, Q1 we said was softer. A bit of that was reflected by the weather, but that was also reflected by the war conditions. But considering the things that they have to overcome, we just have such a fantastic team in Ukraine and we would like to thank them for everything they do because it really is difficult conditions that I don't think any of us would want to trade. And Germany did really, really well. Solid momentum. We are seeing the change in mix continue where we are getting more fee-for-service revenue. Maybe as a consequence of the environment, but also a consequence of the varied proposition that we have there. Our expansion on BDPs continues, and it is really important for us in terms of the future. So that is very good to see. The number of tests is up by 4%, which is good progression; 40.3 million tests were produced, which generated very solid revenue of 205.1 million, up 8.5%. So very good continued improvement in the margin. You can see that that is a significant improvement the team has achieved there. So, very pleasing to see. 40.3 is a positive sign against our 38.7 tests of the comparable quarter. And if you look through from a country mix, it is again relatively stable. And you can see the strength of Ukraine coming through with that. And again, our payer mix continues to increase on a fee-for-service basis. And that will give us much more stability and, of course, opportunity to move prices as we move forward.
So, very positive signs.
So congratulations to everybody in Diagnostic Services. So I will hand over to Anand, who will talk you through a little bit more detail on the financials. And then I'll come back at the end to summarize. Anand, over to you. Thank you, John. I'll describe the quarter as a solid quarter with consistency in us delivering double-digit organic revenue growth and margin accretion as well. So we are pleased with our numbers. I think one number I would highlight is EBIT. So EBIT of 51.2 million. You can see our margin rate is 8% now, which is up 100 basis points year-on-year. So pleased to see underlying profitability being boosted by, as John said, in some areas, tough comps, but we are still growing our margins year-on-year and our organic revenue growth as well. Other profit measures are up year on year as well. As you can see from the page. One I will pull out is EBITDA, which is obviously our best measure of cash profit at 72.7 million. That is up just under 13%, with margin accretion of 50 basis points year-on-year at 11.3%. So we are pleased with that. And as a reminder, in Q2, we paid our dividend of €0.20 per share. That is reflected in our cash flows. From a healthcare perspective, John mentioned that we had some tough comps from last year but we are still pleased with the growth. I would say it was a solid performance. So organic revenue growth of 12.2%. And you can see there was growth in both price and volume, which is very pleasing from an Adjusted EBITDA perspective. It is up year-on-year at 55.6 million. There is margin rate dilution year-on-year of 30 basis points. That is predominantly due to the tough comparables, as I mentioned earlier. And there is also some one-off activity from last year, which if you strip out, then we would be up year-on-year. EBITDAaL relating to the immature Indian hospitals. You can see the loss on those in the quarter was 3.2 million. So it's down a bit on last quarter, but up on last year; those are predominantly due to the hospitals that we opened in Q1, and in line with expectations. But as John Stubbington says, we're pleased to see the India overall company performance perform really well at the numbers that he mentioned earlier. I'd say a very strong month from diagnostics, so solid in healthcare; strong in diagnostics, so organic growth at 10.9%. Again, pleasing to see volume growth as well as price growth across both. EBITDA of 30.3 million, which is very strong with margin rate expansion of 110 basis points at 14.7%. I think obviously, we kind of concluded on the two acquisitions we did in Q2 last year, and it's pleasing to see in both healthcare as well, actually, and in diagnostics, that the synergies we've realized are helping boost our numbers year on year. In other metrics. So leverage trends down. So it is below three, which is good compared to last year, as our increasing profitability offsets the fact that we are keeping our invested base safe from a debt capital and equity capital perspective. You will have seen that we increased and strengthened our liquidity in Q2. So in May, we managed to increase our RCF from 300 million to 400 million. That gives us more scope, optionality, and headroom to take further investment decisions in the future, should we choose to. I've mentioned the dividend we paid of €30 million in Q2; taxes were in line with expectations at 28%, and there was improved performance in cash versus Q1, with net operating cash flow at €73.6 million, and free cash flow at 4.1% of revenues versus 3% last year. And finally, on ROIC, there is an improvement there as well. So 13.6% versus 9.3% last year. So. So, I'd say a good performance on those measures. In terms of CapEx, if you look on the left, you can see this clear blue water between our free cash flow and our growth CapEx, which is good. Our CapEx overall was 29.7 million in the quarter, about 4.6% of revenues. I've mentioned previously that this will be around 6% of revenues for the full year, and we'll stick to that in terms of the type of spending where the money was spent in the quarter; two-thirds was in healthcare services and a third in diagnostics. The maintenance-growth split is 44% to 56% in this quarter. However, looking forward for the full year, we expect to see it revert back to more two-thirds on growth and a third on maintenance. And finally, medical space of just over 1,000,000 square meters. This will move in the quarter, but it is up year on year. And finally, with regards to our mid-term targets to 2028, we still expect to achieve them. So, organic revenue of 3.25 billion, adjusted organic EBITDA of 600 million, leverage under three, and all the other measures highlighted in the bottom right corner, including EBITDAaL. We expect to achieve that for now.
So with that, I'd like to say thank you. And I'll hand back to John to wrap up.
Yeah. We say here solid performance. And that's probably our Englishness that's coming through there. It is really good to see the consistency that we have got with the double-digit organic growth, six consecutive quarters with margin improvement, which is the zone that we want to be in with strong FFS revenue growth. Yeah. That is one of our most important revenue drivers. Really good to see that the synergies from the two acquisitions, which were our largest in our history, have come through and the acquisitions have been embedded well into the organization. And they are very much part of Medicover now. India, as I said before, has been the subject of a lot of conversation. If we go back 12 months, we said that we would start to see the momentum of that coming through. And it is coming through. So strong double-digit revenue growth, even in euro terms with the exchange rate. So, congratulations to all. And we will do what we've said that we're going to do; we'll focus on our execution. We'll focus on making sure we get efficiency, improving our capacity utilization and making sure that when it comes to our price and cost management, that we take the appropriate steps. That means that the customer gets what they need. And that we have a good, strong, sustainable business. And finally, a thank you to all of the people at Medicover; these results have been created due to your hard work. So thank you very much for all you do. Okay. And now we'll go to the Q&A and hand over to the moderator to help us with that.